WHAT ADVERSE REACTIONS TO BIOLOGICAL AGENTS ARE PARADOXICAL?
https://doi.org/10.14412/1995-4484-2018-531-534
Abstract
The paper discusses the appearance of unusual – paradoxical – adverse reactions that occur as a result of treatment of rheumatic diseases with biological agents.
About the Author
Yu. V. Muravyev
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
References
1. Toussirot E, Aubin F. Paradoxical reactions under TNF-blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2(2):e000239. doi: 10.1136/rmdopen-2015-000239
2. Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5:421-31. doi: 10.1586/eci.09.18
3. Toussirot E, Pertuiset E. TNF blocking agents and sarcoidosis: an update. Rev Med Interne. 2010;31:828-37. doi: 10.1016/j.revmed.2010.02.007
4. Joyau C, Veyrac G, Dixneuf V, et al. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012;30:700-6.
5. Fouache D, Goёb V, Massy-Guillemant N, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford). 2009;48:761-4. doi: 10.1093/rheumatology/kep083
6. Baeten D, Kruithof E, van den Bosch F, et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis. 2003;62:829-34. doi: 10.1136/ard.62.9.829
7. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001. doi: 10.1002/art.23835
8. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-40. doi: 10.1016/j.semarthrit.2010.04.003
9. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-55. doi: 10.1016/j.cgh.2010.07.022
10. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209-15. doi: 10.1136/ard.2007.087288
11. Hernandez MV, Sanmarti R, Canete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken). 2013 Dec;65(12):2024-31. doi: 10.1002/acr.22096
12. Thomas L, Canoui-Poitrine F, Gottenberg JE, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry.J Rheumatol. 2012 May;39(5):893-8. doi: 10.3899/jrheum.111347. Epub 2012 Apr 15.
13. Lie E, Lindströ m U, Zverkova-Sandströ m T, et al. The effect of TNF inhibitor treatment on occurrence of anterior uveitis in anky-losing spondylitis: results from the Swedish biologics register. Arthritis Rheum. 2015;67:1271-2.
14. Jimenez-Boj E, Stamm TA, Sadlonova M, et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis. 2012;71:1868-71. doi: 10.1136/annrheumdis-2012-201897
15. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56:2715-18. doi: 10.1002/art.22811
16. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month,multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176
17. Jost C, Hermann J, Caelen Lel-S, et al. New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis. BMJ Case Rep. 2009;2009. pii: bcr09.2008.0845.
18. Kato K, Satoh T, Nishizawa A, Graninger W. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol. 2011;91:362-3. doi: 10.2340/00015555-1042
19. Florent A, Albert C, Giacchero D, Graninger W. Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Joint Bone Spine. 2010;77:626-7.
20. doi: 10.1016/j.jbspin.2010.09.015
21. Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol. 2010;90:183-5. doi: 10.2340/00015555-0777
22. Laurent S, Le Parc JM, Clerici T, et al. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol. 2010;163:1364-5. doi: 10.1111/j.1365-2133.2010.10005.x
23. Palmou-Fontana N, Sanchez Gavino JA, McGonagle D, et al. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology (Basel). 2014;228:311-3. doi: 10.1159/000362266
24. Puig L, Morales-Munera CE, Lopez-Ferrer A, et al. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in apatient with psoriatic arthritis: case report and review. Dermatology (Basel). 2012;225:14-7. doi: 10.1159/000339864
25. Hay RA, Pan JY. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol. 2014;39:751-2. doi: 10.1111/ced.12392
26. Carija A, Ivic I, Marasovicc-Krstulovicc D, et al. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab. Rheumatology (Oxford). 2015;54:2114-6. doi: 10.1093/rheumatology/kev263
27. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496-503. doi: 10.1038/nrgastro.2012.125
28. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch
29. Ophthalmol. 2009;127:819-22. doi: 10.1001/archophthalmol.2009.141
30. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317-23. doi: 10.1016/j.ophtha.2006.04.038
31. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65:1631-4. doi: 10.1136/ard.2006.052092
32. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696-701. doi: 10.1136/ard.2008.092585
33. Le Garrec J, Marcelli C, Mouriaux F. Can tumor necrosis factor inhibitors induce sclero-uveitis? J Fr Ophtalmol. 2009;32:511.e1-6.
34. Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41:503-10. doi: 10.1016/j.semarthrit.2011.05.005
Review
For citations:
Muravyev Yu.V. WHAT ADVERSE REACTIONS TO BIOLOGICAL AGENTS ARE PARADOXICAL? Rheumatology Science and Practice. 2018;56(4):531-534. (In Russ.) https://doi.org/10.14412/1995-4484-2018-531-534
Views:
811
Email this article 